News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Nicholas Morcos, MD

Articles by Nicholas Morcos, MD

© TuYyo/shutterstock.com

MAO Inhibitors: Is Concomitant Use Safe or Too Risky?

ByNicholas Morcos, MD,Jolene R. Bostwick, PharmD, BCPS, BCPP

September 15th 2017

MAOIs deserve special consideration in the treatment of refractory depression. Here's a case in point.

Latest Updated Articles

MAO Inhibitors: Is Concomitant Use Safe or Too Risky?
Published: September 15th 2017 | Updated:

Trending on Psychiatric Times

Lecanemab or Lithium for Alzheimer Disease Dementia? New Data Change Everything

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD

© 2025 MJH Life Sciences^®

All rights reserved.